Pioneer Group is a leading force in life sciences and tech, providing cutting-edge lab and office spaces, investment, and expertise to fuel innovation. We support ambitious start-ups, scale-ups, and established firms with world-class facilities, strategic funding, and tailored business guidance.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells ( Opti-Heps) with functional relevance comparable to human primary cells. Our Opti-Heps effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our Opti-Heps successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.
No data available
No data available
No data available
No data available
No data available
No data available
Protogenia Consulting Ltd offers non-clinical and early clinical development consultancy services, with more than 15 years' outsourcing and project management experience gained through virtual and mid-sized pharmaceutical companies. The services offered include: strategic planning to enable early clinical development and product registration; non-clinical and clinical project management; regulatory submission writing/review/sign-off (e.g. CTA/IND, MAA/NDA, IMPD and IB); and CRO selection and study management – clinical (up to Phase 2) and non-clinical (toxicology, safety pharmacology, ADME, bioanalysis). In addition, we have a broad network of contacts, for expert advice on IP, CMC, analytical services, regulatory affairs and quality assurance.
The Provence Promotion economic development agency has been supporting business investment in Provence for close to two decades. The agency was created by the Bouches-du-Rhône Departmental Government and the Chamber of Commerce and Industry for Marseille Provence, with the Aix-Marseille-Provence Metropolis later joining as a third partner.